Young In the News
WHAT: Scientists have identified a group of genetic mutations in patients with aplastic anemia, which likely will help doctors optimize treatment for this rare and deadly blood condition. The study, appearing in the New England Journal of Medicine, could lead to tailor-made treatment plans for aplastic anemia patients as part of the emerging precision medicine movement. It is the largest study of its kind to examine gene mutations in aplastic anemia, the scientists note.
Prognosis and treatment for aplastic anemia require tailoring based on which mutations patients have among a handful of leukemia-related genes, according to a new study from researchers including NHLBI's Dr. Neal S. Young.
This NIH Catalyst article highlights the NHLBI's Dr. Neal Young. Forty years ago, a diagnosis of severe aplastic anemia meant almost certain death. Today, however, thanks to the work of Dr. Neal Young and others, the survival rate for this rare disease is above 80 percent.
NIH researcher and Elsevier editor Neal S. Young honored for solving aplastic anemia and other medical puzzles.
For years, patients with severe aplastic anemia died within months of developing the rare blood disease. Dr. Neal Young has increased the survival rate to 80 percent.
Dr. Neal Young, chief of NHLBI's Hematology Branch, received the Sammie in the Science and Environment category.
One especially inspiring moment came near the end of the event, when Dr. Neal Young, chief of the Hematology Branch at the National Heart, Lung, and Blood Institute at NIH, discussed his efforts to come up with a new treatment for aplastic anemia, a rare blood disorder.
This medal recognizes a federal employee for a significant contribution to the nation in activities related to science and environment (including biomedicine, economics, energy, information technology, meteorology, resource conservation, and space). Because of Dr. Neal Young’s efforts, his clinic at NIH is today considered one of the world’s major referral centers for patients with bone marrow failure syndromes, including aplastic anemia.
The Aplastic Anemia & MDS International Foundation is pleased to announce that AA&MDSIF Medical Advisory Board member, Dr. Neal Young, has just been awarded the 2012 Samuel J. Heyman Service to America Science and Environment medal.
Neal Young, chief of the hematology branch at the National Heart, Lung, and Blood Institute of the National Institutes of Health, was honored with the Science and Environment Medal for groundbreaking research and treatments for patients with bone marrow failure diseases, including the rare and once deadly blood disorder known as aplastic anemia.
"The idea that you would treat the immune system for the anemia was novel. .?.?. It was a scientific insight with immediate repercussions," said Dr. Young of the NHLBI. Dr. Young's breakthrough research on aplastic anemia, a rare blood disease, led to his selection as a finalist for one of the Samuel J. Heyman Service to America Medals ("Sammies") in the Science and Environment category.
Dr. Young of the NHLBI conceived, designed and headed the first multicenter clinical trial in the United States for immunosuppressive therapy for aplastic anemia. The regimen he developed for this blood disease has become standard therapy for patients all over the world.
The NHLBI's Dr. Neal Young shares highlights from his breakthrough research on aplastic anemia, a rare blood disease, that led to his selection as a finalist for one of the Samuel J. Heyman Service to America Medals ("Sammies") in the Science and Environment category.
In the spring/summer issue of Johns Hopkins Medicine Magazine, Hematology branch chief and Hopkins alum Neal Young reflects on the joys of working at the NIH.
Dunbar and colleagues report that the drug Eltrombopag can improve the blood cell counts of some people who have a severe form of aplastic anemia that is unresponsive to standard therapies.
In his work at the National Institutes of Health (NIH), Dr. Neal Young has combined pioneering basic laboratory science, clinical research protocols, and direct patient care to save the lives of thousands of people suffering from a blood disorder that wipes out the cells in the bone marrow, including red blood cells that carry oxygen, white blood cells that fight infection and platelets that help clot the blood.
Telomeres have been linked to numerous diseases over the years, but how exactly short telomeres cause diseases and how medicine can prevent telomere erosion are still up for debate.
The NHLBI's Dr. Neal Young was profiled by The Washington Post for his research on life-saving treatments for aplastic anemia and his clinical and basic studies of other blood diseases. "I love my job and NIH. There is tremendous intellectual freedom. I can take care of patients in a very special way, focus on unusual or rare diseases and receive support to do transformative work," said Dr. Young.